AbbVie today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.
Study results will be orally presented on Wednesday, October 11, at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin.
“Patients with moderate to severe atopic dermatitis often face relentless itch and inflammatory skin symptoms that can impact their everyday lives,” said Mudra Kapoor, MD., vice president, global medical affairs, immunology, AbbVie. “These results reinforce our commitment to providing an effective, long-term treatment option for those living with this debilitating disease and other chronic, immune-mediated conditions.”
“We are encouraged by these results as they solidify upadacitinib’s potential to improve care for people living with atopic dermatitis,” said Jonathan Silverberg, M.D., Ph.D., MPH, professor of dermatology and director of clinical research at the The George Washington University School of Medicine and Health Sciences. “While upadacitinib has been shown to be an effective treatment option for patients with atopic dermatitis in the short term, these data demonstrate a consistent safety profile and efficacy with long-term treatment.”
👉 AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis – Oct 11, 2023
